Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
We have developed a transgenic mouse model of Type 1 Diabetes (T1D) in which human GAD65 is expressed in pancreatic β-cells, and human MHC-II is expressed on antigen presenting cells.
|
30733517 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Next-generation targeted sequencing of HLA-DRB1 and HLA-DRB3, -DRB4, and -DRB5 (abbreviated as DRB345) provides high resolution of functional variant positions to investigate their associations with type 1 diabetes risk and with autoantibodies against insulin (IAA), GAD65 (GADA), IA-2 (IA-2A), and ZnT8 (ZnT8A).
|
31127057 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
As linear epitopes are sparsely described for GAD65 in T1D, we aimed to identify and thoroughly characterize two GAD65 antibodies using immunoassays.
|
31207885 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
A membrane-bound enzyme on the pancreatic beta-cells, glutamic acid decarboxylase 65 (GAD65), is one of the main autoantigens in type 1 diabetes.
|
31009057 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy.
|
30352895 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The GAD65 and IA-2 antibodies (Abs) are biomarkers of the development of type 1 diabetes mellitus (T1DM) in both children and adults.
|
30727763 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Since GAD65 is intracellularly located and associated with type 1 diabetes mellitus and different clinical neurological phenotypes such as CA, stiff-person syndrome, and epilepsy, some researchers have argued that anti-GAD65 Abs have no pathogenic roles.
|
30343467 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The presence of IA-2var-specific AAb in relatives was associated with accelerated progression to T1D in those positive for AAb to GAD65 and/or insulin but negative in the standard test for IA-2 AAb.
|
31167877 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
HLA-DR3-DQ2<sup>+</sup>huCD4<sup>+</sup>IA/IE<sup>-/-</sup>RIP.B7.1<sup>+</sup> mice spontaneously developed autoimmune diabetes (incidence 46% by 35 weeks of age), accompanied by numerous hallmarks of human type 1 diabetes (autoantibodies against GAD65 and proinsulin; pancreatic islet infiltration by CD4<sup>+</sup>, CD8<sup>+</sup> B220<sup>+</sup>, CD11b<sup>+</sup> and CD11c<sup>+</sup> immune cells).
|
31612266 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
The N-terminal truncated GAD65 isoform was significantly less recognized in GAD65Ab-positive people with stiff-person syndrome (P=0.002) and in healthy individuals (P=0.0001) than in people with Type 1 diabetes.
|
30264481 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
For the subjects diagnosed as T1D, mean C-peptide was 0.63 ± 0.51 nmol/L (1.91 ± 1.53 ng/mL), with 16 (16.2%) IA2 positive, 53 (53.5%) GAD-65 positive, and 10 (10.1%) positive for both autoantibodies.
|
30710658 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Patients with ECL-GAD65 antibody-negative share a similar phenotype with type 2 diabetes mellitus patients, whereas patients with ECL-GAD65 antibody-positive resemble those with type 1 diabetes mellitus.
|
31769235 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, donor islet exosome cargo analysis showed time-specific increase in islet autoantigen, glutamic acid decarboxylase 65 (GAD65), implicated in T1D autoimmunity.
|
30801971 |
2019 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Among patients with ketosis-prone diabetes (KPD), characterized by presentation with diabetic ketoacidosis (DKA), >60% of adults lack three classic islet autoantibodies-IA-2, GAD65, and ZnT8 Abs-associated with type 1 diabetes.
|
30327357 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
β-cell autoantibodies against insulin (IAA), GAD65 (GADA) and IA-2 (IA-2A) precede onset of childhood type 1 diabetes (T1D).
|
28941965 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies.
|
29636076 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, we examined the frequency of circulating CD4+CXCR5+ and CD4+CXCR5+ICOS+ (representing Tfh) cells as well as serum levels of anti-glutamic acid decarboxylase 65 (GAD65) and islet cell autoantibodies (ICA) in children with type I diabetes.
|
30644700 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here we show that autoreactive CD8<sup>+</sup> Tscm specific for β-cell antigens GAD65, insulin, and IGRP are present in patients with type 1 diabetes (T1D).
|
29506985 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Additionally, human islet EVs induce an increase in antibodies against glutamic acid decarboxylase 65 (GAD65) in T1D PBMCs.
|
30307543 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
We present here the correlation of picomolar affinities between surface-plasmon and electrochemical immunoassays for the binding of serum glutamic acid decarboxylase 65 autoantibody (GADA), a biomarker of type 1 diabetes (T1D), to its antigen GAD-65.
|
30213185 |
2018 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Notably, logistic regression analysis suggested that DQ8/8 patients had an increased risk to be diagnosed with tGADA (<i>P</i> = 0.003) compared with fGADA (<i>P</i> = 0.09). tGADA had a higher diagnostic sensitivity for type 1 diabetes than both fGADA and RSRGADA.
|
28028075 |
2017 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Type 1 diabetes autoantibodies (GAD65, Islet, and ZincT8) and monogenic diabetes genetic tests were negative.
|
27807935 |
2017 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Autoimmune or type 1 diabetes mellitus was ruled out with normal levels of anti-glutamic acid decarboxylase 65 (GAD65) antibody, zinc transporter 8 (ZnT8) antibody, and islet antigen-2 (IA-2) antibody.
|
29254501 |
2017 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
Accordingly, the anchoring of GAD65 to exosome-mimetic liposomes strongly boosted antigen presentation and T-cell activation in the context of the human T1D susceptibility haplotype HLA-DR4.
|
27872147 |
2017 |
Diabetes Mellitus, Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
BEFREE |
It seems probable that treatment with GAD65-alum 20 µg sc can preserve residual beta cell function in T1D, but efficacy needs to be improved.
|
28480759 |
2017 |